Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Notes Payables (2016 - 2017)

Gyre Therapeutics has reported Notes Payables over the past 3 years, most recently at $5.1 million for Q4 2017.

  • Quarterly Notes Payables fell 73.79% to $5.1 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2017, down 73.79% year-over-year, with the annual reading at $5.1 million for FY2017, 73.79% down from the prior year.
  • Notes Payables was $5.1 million for Q4 2017 at Gyre Therapeutics, down from $5.5 million in the prior quarter.
  • Over five years, Notes Payables peaked at $34.8 million in Q3 2015 and troughed at $5.1 million in Q4 2017.
  • The 3-year median for Notes Payables is $24.5 million (2016), against an average of $20.8 million.
  • Year-over-year, Notes Payables decreased 14.69% in 2016 and then tumbled 81.5% in 2017.
  • A 3-year view of Notes Payables shows it stood at $33.7 million in 2015, then tumbled by 42.5% to $19.4 million in 2016, then tumbled by 73.79% to $5.1 million in 2017.
  • Per Business Quant, the three most recent readings for GYRE's Notes Payables are $5.1 million (Q4 2017), $5.5 million (Q3 2017), and $5.8 million (Q2 2017).